{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:58:16Z","timestamp":1792706296025,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recently, the prognosis of metastatic renal cell carcinoma (mRCC) has improved owing to the development of immunotherapy using immune checkpoint inhibitors (ICIs). However, there have been few studies on the therapeutic effect of ICIs in bone metastases from renal cell carcinoma (RCC). We report a case in which pulmonary and humeral metastases from RCC were significantly ameliorated using ICIs, while surgery for a pathological fracture of the humerus significantly improved the patient\u2019s quality of life (QoL). A 70-year-old man who underwent a left nephrectomy for RCC developed multiple pulmonary metastases and humeral metastasis with a pathological fracture one year after surgery, and combined treatment with nivolumab and ipilimumab was initiated. After four courses of ICI treatment, multiple pulmonary metastases had almost disappeared, and the tumor at the fracture site had shrunk remarkably. However, the shoulder joint function had decreased due to the fracture, worsening his QoL. Therefore, he underwent surgery and returned to normal daily life one month after. Postoperative histopathological examination of bone and soft tissue at the fracture site revealed no malignancy. To our knowledge, this is the first case report of complete remission of bone metastasis of RCC based on histopathological examination with ICI treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2022.980456","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T08:53:41Z","timestamp":1664268821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Yohei","family":"Asano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kadono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"Ljungberg","year":"2011","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: A population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e83026","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2007.07.002","article-title":"Burden of bone disease","author":"Kinnane","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.236","article-title":"Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma","volume":"108","author":"Motzer","year":"2013","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/annonc\/mdq342","article-title":"Prognostic factors for progression free survival and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma","volume":"22","author":"Patil","year":"2011","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3892\/ol.2020.12130","article-title":"Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma","volume":"20","author":"Negishi","year":"2020","journal-title":"Oncol Lett"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.707214","article-title":"Immune checkpoint inhibitor in first-line treatment of metastatic renal cell carcinoma: A review of current evidence and future directions","volume":"11","author":"Tung","year":"2021","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L","article-title":"Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand)","volume":"29","author":"Hudak","year":"1996","journal-title":"Am J Ind Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e5531","DOI":"10.7759\/cureus.5531","article-title":"Complete remission of bone metastases in renal cell carcinoma with nivolumab","volume":"11","author":"Vuyyala","year":"2019","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4172\/2471-8556.1000125","article-title":"Complete remission of liver and bone metastases after nivolumab treatment in a patient with renal cell carcinoma: The potential implication of MLH1 mutations","volume":"3","author":"Marsh","year":"2017","journal-title":"Oncol Cancer Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"B20","article-title":"Management of metastatic bone disease algorithms for diagnostics and treatment","volume":"36","author":"Jehn","year":"2016","journal-title":"Anticancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0093","article-title":"Spine radiosurgery in the management of renal cell carcinoma metastases","volume":"13","author":"Taunk","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1097\/00003086-198912000-00027","article-title":"Metastatic disease in long bones. a proposed scoring system for diagnosing impending pathologic fractures","author":"Mirels","year":"1989","journal-title":"Clin Orthop Relat Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: Experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1480301","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1431088","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14933","article-title":"Complete response of bone metastasis in non-small cell lung cancer with pembrolizumab: Two case reports","volume":"41","author":"Asano","year":"2021","journal-title":"Anticancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.871675","article-title":"The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-Small-Cell lung cancer","volume":"12","author":"Asano","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.980456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T08:53:51Z","timestamp":1664268831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.980456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2022.980456"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.980456","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"980456"}}